Impact Investing: Healthcare Startups vs The Stock Market

For retail investors, it has only become possible to invest in startups and private companies over the last 1-2 decades. This is largely the result of new legislation like Regulation CF and the proliferation of startup investing platforms. Prior to this, only well-connected investors with a significant net worth had the opportunity to invest in these companies.

continue reading >

The Bioverge Podcast: Evolving Failures in an Evolving Pandemic and What Needs to Be Done

Dr. Eric Topol, founder and director of the Scripps Research Translational Institute, sits down with Neil to discuss the COVID-19 delta variant, our failures to evolve with the virus, and what steps need to be taken to combat the ongoing pandemic.

continue reading >

The Bioverge Podcast: Democratizing Entrepreneurship

Juan Scarlett, managing director of OneValley Ventures, sits down with Neil to discuss OneValley's efforts to democratize entrepreneurship and his approach investing in pre-seed and seed funding rounds.

continue reading >

Healthcare-Focused Impact Investing: Another Way To Invest For Change

Healthcare provides another avenue in which investors can do well by doing good.

continue reading >

Enveda Investment Thesis

Bioverge recently invested in Enveda’s $51 million Series A led by Lux Capital.  Enveda is biotechnology startup focused on harnessing the power of nature’s chemistry to develop next generation small-molecule therapeutics.

continue reading >

Managed marketplaces and reality TV: How a new generation of gatekeepers is opening biotech up to amateur investors

"The average person will never get the chance to invest in a future unicorn like Moderna: The type of private equity deals that brought the now-famous biotech to the world are done in country clubs and coffee houses in a select few places, leaving anyone who is not a hedge fund manager, venture capitalist or disgustingly rich individual out of the game."

continue reading >

The Bioverge Podcast: Why the FDA Was Right to Approve Biogen's Aduhelm

James Valentine, an attorney with Hyman, Phelps & McNamara specializing in regulatory law, sits down with Neil to discuss the FDA’s accelerated approval of Biogen’s Aduhelm for Alzheimer’s disease and offers a contrarian take on the controversy.

continue reading >

Juno Diagnostics Investment

Juno Diagnostics, a San Diego based genetic diagnostics company in the Bioverge portfolio, just raised a $25 million Series A round led by Perceptive Xontogeny Venture Fund in May 2021.

continue reading >

The Bioverge Podcast: Managing the Challenges of Scaling Cell and Gene Therapies

Amy DuRoss, co-founder and CEO of Vineti, sits down with Neil to discuss how the company’s platform technology addresses the unique supply chain management challenges of cell and gene therapy companies.

continue reading >
Investing

Impact Investing: Healthcare Startups vs The Stock Market

For retail investors, it has only become possible to invest in startups and private companies over the last 1-2 decades. This is largely the result of new legislation like Regulation CF and the proliferation of startup investing platforms. Prior to this, only well-connected investors with a significant net worth had the opportunity to invest in these companies.

Continue Reading >
Media

The Bioverge Podcast: Evolving Failures in an Evolving Pandemic and What Needs to Be Done

Dr. Eric Topol, founder and director of the Scripps Research Translational Institute, sits down with Neil to discuss the COVID-19 delta variant, our failures to evolve with the virus, and what steps need to be taken to combat the ongoing pandemic.

Continue Reading >
Media

The Bioverge Podcast: Democratizing Entrepreneurship

Juan Scarlett, managing director of OneValley Ventures, sits down with Neil to discuss OneValley's efforts to democratize entrepreneurship and his approach investing in pre-seed and seed funding rounds.

Continue Reading >
Investing

Healthcare-Focused Impact Investing: Another Way To Invest For Change

Healthcare provides another avenue in which investors can do well by doing good.

Continue Reading >
Investing

Enveda Investment Thesis

Bioverge recently invested in Enveda’s $51 million Series A led by Lux Capital.  Enveda is biotechnology startup focused on harnessing the power of nature’s chemistry to develop next generation small-molecule therapeutics.

Continue Reading >
Press

Managed marketplaces and reality TV: How a new generation of gatekeepers is opening biotech up to amateur investors

"The average person will never get the chance to invest in a future unicorn like Moderna: The type of private equity deals that brought the now-famous biotech to the world are done in country clubs and coffee houses in a select few places, leaving anyone who is not a hedge fund manager, venture capitalist or disgustingly rich individual out of the game."

Continue Reading >
Media

The Bioverge Podcast: Why the FDA Was Right to Approve Biogen's Aduhelm

James Valentine, an attorney with Hyman, Phelps & McNamara specializing in regulatory law, sits down with Neil to discuss the FDA’s accelerated approval of Biogen’s Aduhelm for Alzheimer’s disease and offers a contrarian take on the controversy.

Continue Reading >
Startups

Juno Diagnostics Investment

Juno Diagnostics, a San Diego based genetic diagnostics company in the Bioverge portfolio, just raised a $25 million Series A round led by Perceptive Xontogeny Venture Fund in May 2021.

Continue Reading >
Media

The Bioverge Podcast: Managing the Challenges of Scaling Cell and Gene Therapies

Amy DuRoss, co-founder and CEO of Vineti, sits down with Neil to discuss how the company’s platform technology addresses the unique supply chain management challenges of cell and gene therapy companies.

Continue Reading >
Prev Next